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Recent findings demonstrate that dendritic cells in prostate tumors induce immune tolerance in tumor antigen-specific
CD8
+ T cells. We propose that DC tolerogenicity can be regulated by expression of Foxo3; silencing Foxo3 expression
enhances anti-tumor immune responses and renders FOXO3 a potential target for immunotherapy.
Dendritic cells (DC) are among the most
versatile cells of the immune system. DC
are essential to the initiation of a product-
ive immune response by presenting Ag to
T cells and secreting pro-inflammatory
cytokines, but are also responsible for
controlling over-active immunity by regu-
lating immune tolerance. While tolerance
is an essential component of preventing
autoimmune disease, it is also a complica-
tion and major hurdle to overcome in the
quest to improve immune-based therapies
for cancer.
Tumors create a highly complex micro-
environment rich in cytokines, chemo-
kines and other factors that attract various
populations of immune cells including DC
and T cells. Although the infiltration of
immune cells is seemingly beneficial, the
suppressive tumor microenvironment
(TME) quickly neutralizes anti-tumor
responses and cells such as antigen-specific
cytotoxic T lymphocytes (CTL) with the
potential to control tumor burden lose
their function.
1 Several therapies have aimed
to target and neutralize DC-produced
immunosuppressive factors such as
Interleukin (IL)-10, indoleamine-2,3-
dioxygenase (IDO), vascular endothelial
growth factor (VEGF) and epidermal
growth factor (EGF) in an attempt to
enhance T cell responses to tumors.
2
However, inhibition of select suppressive
factors has proven to be insufficient for
sustaining anti-tumor immunity. There-
fore, we sought to gain a better under-
standing of the mechanisms that regulate
tumor-associated DC (TADC)-induced
immune tolerance.
We initially confirmed that tolerogenic
mediators present in the tumor micro-
environment (IDO, Arginase, TGF )
dampened responsiveness of adoptively
transferred CD8
+ T cells. However, block-
ing these TADC-derived tolerogenic med-
iators, individually or in combination,
only transiently enhanced T cell effector
function. In contrast, depleting TADC
restored anti-tumor effector functions of
tumor-infiltrating T cells. Subsequent in
vitro studies demonstrated that TADC
were not only poor stimulators of T cells,
but they actively induced T cell tolerance
and were capable of inducing suppressive
activity, confirming our previous observa-
tions using an adoptive transfer model
(Fig.1A).
3 Importantly, our results obser-
ved in the TRansgenic Adenocarcinoma of
the Mouse Prostate (TRAMP) model were
consistent with studies using TADC
isolated from human prostate tumor tissue
sections suggesting that our results may
have significant clinical relevance.
4
Analysis of gene expression patterns in
TRAMP TADC revealed increased expres-
sion of chemokines (Cxcl10, Cxcl9 and
Ccl5), growth factors (Vegfa and Tgf ), and
other genes associated with tolerance
(Ido1, Arg1, Cd274). Additionally, increa-
sed expression of the gene Foxo3 was
observed in TADC compared with non-
tumor-associated prostate DC (Fig.1A).
FOXO3 is a member of the Forkhead box
transcription factor class-O family and was
previously reported to play a role in the
regulation of DC function through a
“reverse signaling” process mediated by
CTLA-4 interaction with B7 molecules,
leading to increased in IDO levels.
5
Therefore, to determine the role of Foxo3
expression in controlling TADC tolero-
genicity, we silenced Foxo3 expression
using siRNA and observed reduced DC
tolerogenicity, decreased expression of
suppressive factors Tgf , Arg1 and Ido1
and a concomitant increase in expression
of the co-stimulatory molecule CD80 and
the pro-inflammatory cytokine, IL-6.
4
Interestingly, we previously reported
that TRAMP TADC could be activated
or “licensed” in situ by tumor-antigen
specific CD4
+ T cells, resulting in more
stimulatory DC.
6 We now observed that
the activation induced by CD4
+ helper
cells also resulted in reduced TADC
tolerogenicity concomitant with down-
regulation of Foxo3 expression.
4 In general,
our findings suggest that the downregula-
tion of Foxo3 allows for the conversion of
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tolerogenic DC to immune stimulatory,
including increased expression of B7,
MHC and CD40 molecules as well as an
increase in pro-inflammatory cytokines IL-
12, IL-15 and IL-6 (Fig.1B). These data
suggest that TADC can be a useful target
in immune based therapies and further-
more, that FOXO3 may be part of a
regulatory mechanism that programs the
inflammatory vs. tolerogenic potential of
dendritic cells.
In summary, we conclude that TADC
are critical in determining the effectiveness
of anti-tumor immune responses, espe-
cially with respect to maintaining activa-
tion of Ag-specific CD8
+ T cells. We
reported that TADC tolerogenicity is
regulated by Foxo3 in both murine and
human prostate cancer as well as murine
models of melanoma and renal cell
carcinoma.
4 However, the mechanisms
responsible for increased Foxo3 expression
in TADC as well as the mechanism(s) by
which FOXO3 mediates tolerogenicity are
unclear and are currently under investiga-
tion. Foxo3 expression may be induced
in response to stimuli such as reactive
oxygen species
7 in the TME or in response
to interactions with other inflammatory
cells (e.g., macrophages or mast cells) and
their products within the TME. FOXO3
may induce expression of genes associated
with tolerance, such as Ido, Tgf , and/or Il-
10. A second possible hypothesis is that
FOXO3 may play a less direct or active
role in inducing expression of genes asso-
ciated with tolerance, but rather, may medi-
ate the inactivation of pro-inflammatory
signals such as inhibition of NFkBo r
STATs. Lin et al. previously reported that
FOXO3 regulates helper T cell activation
to control autoimmunity by inhibiting
NFkB.
8 This is an interesting perspective
as similar mechanisms have been described
involving transcription factors overex-
pressed in inflammatory cells that infilt-
rate tumors, such as p53.
9 Elucidation of
these mechanisms may be critical to
unveiling the balance between inflam-
mation and tolerance in DC.
In terms of therapy, given that FOXO3
is also important for cell cycle regulation
by activating genes that induce apopto-
sis,
10 it may be most beneficial to utilize an
approach that specifically targets silencing
expression to dendritic cells, thus prevent-
ing downregulation of Foxo3 in tumor
cells. One such approach currently under
investigation is to administer small mole-
cule and peptide-based inhibitors to
FOXO3. Ideally, these inhibitors could
be linked to molecules that would be
taken up by DC-specific receptors, such as
DEC-205. A second strategy may be to
inhibit DNA binding by administering
decoy DNA containing the motif recog-
nized by Foxo3 thus preventing the
induction of Foxo3 regulated genes asso-
ciated with tolerance. These discoveries
may have great impact for not only
efficiently targeting and improving DC
function in cancer immunotherapy, but
may also have significant implications for
designing therapeutics to utilize DC to
dampen inflammation in autoimmune
disease.
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